Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
How can we best monitor 5-FU administration to maximize benefit to risk ratio?
Goirand F, Lemaitre F, Launay M, Tron C, Chatelut E, Boyer JC, Bardou M, Schmitt A. Goirand F, et al. Among authors: launay m. Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1303-1313. doi: 10.1080/17425255.2018.1550484. Epub 2018 Nov 23. Expert Opin Drug Metab Toxicol. 2018. PMID: 30451549 Free article. Review.
Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation.
Thomas F, Maillard M, Launay M, Tron C, Etienne-Grimaldi MC, Gautier-Veyret E, Haufroid V, Pallet N, Royer B, Narjoz C, Schmitt A; Groupe de Pharmacologie Clinique Oncologique (GPCO-UNICANCER). Thomas F, et al. Among authors: launay m. Ann Oncol. 2021 Jun;32(6):810-811. doi: 10.1016/j.annonc.2021.02.020. Epub 2021 Mar 1. Ann Oncol. 2021. PMID: 33662499 Free article. No abstract available.
Ceftazidime dosing in obese patients: is it time for more?
Fanton D'Andon C, Correia P, Rigaill J, Kably B, Perinel-Ragey S, Launay M. Fanton D'Andon C, et al. Among authors: launay m. Expert Opin Drug Metab Toxicol. 2022 Apr;18(4):277-284. doi: 10.1080/17425255.2022.2080052. Epub 2022 May 30. Expert Opin Drug Metab Toxicol. 2022. PMID: 35583387 Review.
Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.
Maillard M, Launay M, Royer B, Guitton J, Gautier-Veyret E, Broutin S, Tron C, Le Louedec F, Ciccolini J, Richard D, Alarcan H, Haufroid V, Tafzi N, Schmitt A, Etienne-Grimaldi MC, Narjoz C, Thomas F; Groupe de Pharmacologie Clinique Oncologique (GPCO). Maillard M, et al. Among authors: launay m. Br J Clin Pharmacol. 2023 Feb;89(2):762-772. doi: 10.1111/bcp.15536. Epub 2022 Oct 3. Br J Clin Pharmacol. 2023. PMID: 36104927 Free PMC article.
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Thomas F, Launay M, Guitton J, Loriot MA, Boyer JC, Haufroid V, Etienne-Grimaldi MC, Royer B; GPCO-UNICANCER Group. Thomas F, et al. Among authors: launay m. Clin Pharmacol Ther. 2023 Mar;113(3):471-472. doi: 10.1002/cpt.2772. Epub 2022 Nov 22. Clin Pharmacol Ther. 2023. PMID: 36412238 No abstract available.
Antifungal Drugs TDM: Trends and Update.
Kably B, Launay M, Derobertmasure A, Lefeuvre S, Dannaoui E, Billaud EM. Kably B, et al. Among authors: launay m. Ther Drug Monit. 2022 Feb 1;44(1):166-197. doi: 10.1097/FTD.0000000000000952. Ther Drug Monit. 2022. PMID: 34923544 Review.
124 results